Full-Time

Senior Software Engineer

Probably Genetic

Probably Genetic

11-50 employees

Free at-home genetic testing for diagnosis

Compensation Overview

$150k - $210k/yr

+ Equity Grants

San Francisco, CA, USA

Hybrid

Hybrid role with on-site requirement: 3 days per week in San Francisco (Tue–Thu).

Category
Software Engineering (1)
Required Skills
Python
React.js
Github Actions
Postgres
TypeScript
AWS
Terraform
Django
Requirements
  • Proven experience developing full-stack applications, with a back-end focus and a passion for shipping high quality code at velocity
  • Experience in a range of software languages and frameworks included in our tech stack: Languages: Python (Django) and Typescript (React)
  • Tools/Infrastructure: PostgreSQL, AWS, Terraform, GitHub Actions
  • Experience designing and building scalable systems used by external users
  • Track-record of solving extremely difficult, ambiguous problems
  • Excellent communication skills with ability to can convey your ideals clearly to engineers and non-engineers alike!
Responsibilities
  • Work across teams to rapidly transform key requirements into front-end releases that meaningfully improve how patients engage with our product
  • Create APIs, laboratory integrations, bioinformatic tooling, and ML infrastructure using Python, Django, PostgreSQL databases, and AWS services
  • Develop the phenotyping product and biotech data platform frontends in React & Typescript
  • Regularly review your team’s pull requests and technical proposal documents to maintain high standards and architectural quality
  • Present your work to relevant stakeholders, monitoring outcomes, and integrating patient feedback
  • Contribute to a culture of continuous improvement at a high velocity by optimizing development processes
  • Own business goals and writing technical design specifications to find more patients, grow revenue, and increase margins
  • Collaborate with Product and other business teams to implement solutions which drive customer value
  • Work with cross-functional stakeholders to refine business processes and develop software to automate those processes
Desired Qualifications
  • Expertise with healthcare data, bioinformatics, genetics, ML infrastructure, or growth marketing
  • Expertise in HIPAA compliance and security best practices
  • Expertise in product development practices such as user interviews and product analytics

Probably Genetic offers free at-home genetic testing for people with rare diseases. Patients collect a DNA sample at home, mail it in, and receive physician-reviewed results with genetic counseling and a clinical genetic report. The company funds the tests itself and keeps the data; after de-identification, the aggregated data is sold to research institutions and pharmaceutical companies. Its goal is to help patients get timely diagnoses while funding the program through data-driven partnerships to advance rare-disease research.

Company Size

11-50

Company Stage

Early VC

Total Funding

$11M

Headquarters

San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Slack scales operations to test 230,000 patients, diagnosing over 50%.
  • Over 50% diagnosis rate since 2018 with global coverage and insurance options.
  • Recent 2026 partnerships accelerate SCN2A and APBD diagnoses via AI checkers.

What critics are saying

  • Invitae 2024 bankruptcy floods market with cheap exome data, undercutting value.
  • 23andMe's 6.8M genomes commoditize rare variant data in 6-12 months.
  • EU AI Act 2026 enforcement halts de-identified data sales via re-identification.

What makes Probably Genetic unique

  • Targets rare genetic conditions misdiagnosed as autism using free at-home tests.
  • Aggregates de-identified data from tests for sale to pharma and researchers.
  • Partners with SCN2A, APBD, CACNA1A, MED13L Foundations for targeted testing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Unlimited Paid Time Off

Hybrid Work Options

Remote Work Options

Company Equity

Health Insurance

Dental Insurance

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

0%

2 year growth

4%
Trending Topics
Dec 29th, 2023
Calm/Storm: 4,5 Mio. Euro 2023 Investiert – Und 2024 Kann Noch Einmal Blutig Werden

Aus Österreich heraus den aktivsten HealthTech-Fonds Europas zu starten, ist eine Leistung, die sich Lucanus Polagnoli und sein Team auf die Segel, pardon, Fahnen, schreiben können: Doch seit 2023 investiert Calm/Storm Ventures nicht nur in Digital-Health-Startups, sondern hat auch einen eigenen Fonds für Startups aufgelegt, mit dem auch in Startups aus anderen Branchen investiert, solange diese von Österreicher:innen (mit-)gegründet wurden. „Mit insgesamt 17 Neu-Investments ist das Portfolio auf 75 Startup-Unternehmen gewachsen. Zusammen mit 21 Follow-On Transaktionen innerhalb des Portfolios wurden 2023 insgesamt über 4,5 Millionen Euro investiert“, so Calm/Storm-CEO Lucanus Polagnoli zu Trending Topics. Man würde besonders oft in so genannte Stealth-Startups investieren, also Jungfirmen, die noch gar nicht auf dem Markt sind. Ein Beispiel ist Mirror, das neue Startup der ehemaligen Gründer von Gorillas, Kagan Sümer und Ugur Samut. Wert wird auf Diversität gelegt; Die Hälfte der Teams, in die Calm/Storm investieret, sind divers, und 30% aller CEOs seien Frauen

Securities and Exchange Commission
Nov 3rd, 2023
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Cision
Aug 3rd, 2023
The Scn2A Foundation And Probably Genetic Partner To Make Genetic Test

scn2a foundation probably genetic partner to accelerate scn2a diagnosis. . “By increasing the ability to test for rare disorders, there will be a better opportunity to diagnose and treat patients with rare diseases. Lukas and his team are doing amazing work and we’re happy to help in any way we can” said Jason Curry, Founder of The SCN2A Foundation

APBD Research Foundation
Jul 18th, 2023
Foundation partners with Probably Genetic to address diagnostic challenges

Apbdrf is thrilled to announce that the APBD Research Foundation has partnered with Probably Genetic to increase access to genetic testing within its community.